Cerity Partners LLC grew its position in Cencora, Inc. (NYSE:COR - Free Report) by 10.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 39,457 shares of the company's stock after acquiring an additional 3,610 shares during the quarter. Cerity Partners LLC's holdings in Cencora were worth $8,881,000 as of its most recent SEC filing.
A number of other institutional investors have also recently made changes to their positions in the company. New Millennium Group LLC purchased a new position in Cencora in the 2nd quarter valued at $26,000. LRI Investments LLC acquired a new stake in Cencora in the 1st quarter valued at about $31,000. MFA Wealth Advisors LLC acquired a new stake in Cencora in the 2nd quarter valued at about $30,000. Concord Wealth Partners purchased a new position in Cencora in the 3rd quarter worth approximately $30,000. Finally, SYSTM Wealth Solutions LLC purchased a new stake in shares of Cencora in the second quarter valued at approximately $36,000. 97.52% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on COR shares. Leerink Partners reduced their price objective on Cencora from $277.00 to $275.00 and set an "outperform" rating on the stock in a research report on Monday, October 7th. Evercore ISI lifted their target price on shares of Cencora from $250.00 to $285.00 and gave the stock an "outperform" rating in a research note on Thursday, November 7th. Barclays increased their price target on shares of Cencora from $263.00 to $290.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. Wells Fargo & Company lifted their price target on shares of Cencora from $236.00 to $249.00 and gave the company an "equal weight" rating in a research report on Thursday, August 1st. Finally, Robert W. Baird upped their price objective on Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a report on Thursday, November 7th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $271.20.
View Our Latest Stock Report on COR
Cencora Price Performance
COR stock opened at $248.40 on Wednesday. The business's fifty day moving average price is $233.28 and its 200 day moving average price is $231.85. Cencora, Inc. has a 12-month low of $195.83 and a 12-month high of $251.56. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84. The company has a market capitalization of $48.95 billion, a PE ratio of 33.08, a P/E/G ratio of 1.63 and a beta of 0.44.
Cencora Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, November 29th. Shareholders of record on Friday, November 15th will be paid a dividend of $0.55 per share. The ex-dividend date of this dividend is Friday, November 15th. This is a positive change from Cencora's previous quarterly dividend of $0.51. This represents a $2.20 dividend on an annualized basis and a yield of 0.89%. Cencora's dividend payout ratio is 29.29%.
Insider Activity
In related news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total value of $5,208,619.44. Following the completion of the transaction, the chairman now owns 306,752 shares in the company, valued at $74,283,064.32. The trade was a 6.55 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last quarter, insiders sold 93,018 shares of company stock valued at $22,478,942. 15.80% of the stock is currently owned by company insiders.
Cencora Profile
(
Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Read More
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
